Many products sold by companies aren't must-have items. However, healthcare is a necessity. And the healthcare sector is poised to grow over the next decade and beyond with aging populations around ...

Pharmaceutical stocks can bring an element of safety to your portfolio. All of this equals a rather steady stream of revenue ...

Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

The startups are the fourth and fifth drugmakers to file for initial public offerings since late December — the most notable ...

Shares of Evolus made a doubly bullish move Tuesday on a strong preliminary fourth-quarter report and guidance for 2025.

On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII ...

Disc Medicine has finalized the design of the confirmatory trial for its rare blood disorder drug candidate, adding a ...

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...